Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) – Investment analysts at Zacks Small Cap issued their Q1 2024 earnings per share (EPS) estimates for shares of Cocrystal Pharma in a research note issued on Tuesday, April 23rd. Zacks Small Cap analyst D. Bautz forecasts that the company will post earnings per share of ($0.52) for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($2.31) per share. Zacks Small Cap also issued estimates for Cocrystal Pharma’s Q2 2024 earnings at ($0.56) EPS, Q4 2024 earnings at ($0.62) EPS, FY2024 earnings at ($2.28) EPS and FY2025 earnings at ($2.44) EPS.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.13.
Read Our Latest Research Report on Cocrystal Pharma
Cocrystal Pharma Price Performance
Shares of NASDAQ:COCP opened at $1.51 on Friday. The firm has a fifty day simple moving average of $1.49 and a two-hundred day simple moving average of $1.63. Cocrystal Pharma has a 52 week low of $1.33 and a 52 week high of $3.29.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.
Further Reading
- Five stocks we like better than Cocrystal Pharma
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Semiconductor Shakeout: Finding Potential Amidst Turmoil
- What is Insider Trading? What You Can Learn from Insider Trading
- Hasbro’s Management Made All the Right Calls This Quarter
- How to Calculate Return on Investment (ROI)
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.